Investors & Media

Event Details


Relay Therapeutics to Present Clinical Data on RLY‐4008 at ESMO Congress

Sep 11, 2022 at 9:45 AM EDT

Title: Efficacy of RLY‐4008, a highly selective FGFR2 inhibitor in patients (pts) with a FGFR2‐fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)‐naïve cholangiocarcinoma (CCA): ReFocus trial

Abstract Number: LBA12

Session Title: Proffered Paper Session 2: GI, Upper Digestive

September 11, 2022 at 3:45 pm C.E.S.T./9:45 am E.T